Profound Medical (PROF) Expected to Announce Quarterly Earnings on Thursday

Profound Medical (NASDAQ:PROF) is expected to be announcing its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $4.8520 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Profound Medical (NASDAQ:PROF) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.27). Profound Medical had a negative net margin of 264.45% and a negative return on equity of 90.28%. The firm had revenue of $5.98 million during the quarter, compared to the consensus estimate of $10.53 million. On average, analysts expect Profound Medical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Profound Medical Stock Performance

NASDAQ:PROF traded up $0.45 during mid-day trading on Tuesday, reaching $7.15. 105,241 shares of the company’s stock were exchanged, compared to its average volume of 212,255. Profound Medical has a one year low of $3.76 and a one year high of $8.95. The company has a debt-to-equity ratio of 0.07, a quick ratio of 11.17 and a current ratio of 12.52. The business’s fifty day simple moving average is $6.39 and its two-hundred day simple moving average is $6.72. The firm has a market capitalization of $259.69 million, a PE ratio of -5.09 and a beta of 0.73.

Institutional Investors Weigh In On Profound Medical

A number of hedge funds have recently modified their holdings of PROF. Velan Capital Investment Management LP purchased a new stake in Profound Medical in the fourth quarter worth $2,249,000. Raymond James Financial Inc. lifted its holdings in Profound Medical by 5.5% during the second quarter. Raymond James Financial Inc. now owns 941,879 shares of the company’s stock valued at $5,557,000 after purchasing an additional 49,000 shares during the last quarter. FIL Ltd boosted its position in Profound Medical by 16.7% during the fourth quarter. FIL Ltd now owns 2,200,000 shares of the company’s stock worth $17,270,000 after purchasing an additional 315,000 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Profound Medical by 56.8% in the fourth quarter. Goldman Sachs Group Inc. now owns 18,727 shares of the company’s stock worth $147,000 after purchasing an additional 6,787 shares in the last quarter. Finally, Rosalind Advisors Inc. raised its position in shares of Profound Medical by 54.4% in the fourth quarter. Rosalind Advisors Inc. now owns 1,068,955 shares of the company’s stock valued at $8,413,000 after purchasing an additional 376,770 shares during the period. Institutional investors own 47.86% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Lake Street Capital lifted their price target on shares of Profound Medical from $11.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Profound Medical in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Profound Medical currently has an average rating of “Hold” and a consensus price target of $12.00.

Profound Medical Company Profile

Profound Medical Corp is a medical technology company headquartered in Toronto, Canada, that specializes in the development and commercialization of minimally invasive therapeutic solutions using magnetic resonance–guided ultrasound ablation. The company’s proprietary platform delivers focused ultrasound energy to targeted tissue under real-time MR imaging, offering a non-incisional alternative to traditional surgical approaches.

The company’s lead product, the TULSA-PRO system, is designed for the treatment of prostate conditions, including localized prostate cancer and benign prostatic hyperplasia.